|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.86 USD | -1.90% |
|
-3.21% | +34.07% |
| 07/07 | RBC Lifts Price Target on CorMedix to $18 From $17, Keeps Outperform, Speculative Risk | MT |
| 01/07 | North American Morning Briefing : Stock Futures -2- | DJ |
| Capitalization | 81Cr 69Cr 65Cr 60Cr 110.92Cr 6.96TCr 123.86Cr 780.63Cr 294.68Cr 3.26TCr 303.19Cr 296.91Cr 12TCr | P/E ratio 2025 * |
10.2x | P/E ratio 2026 * | 6.05x |
|---|---|---|---|---|---|
| Enterprise value | 66Cr 57Cr 53Cr 49Cr 91Cr 5.7TCr 101.33Cr 638.65Cr 241.09Cr 2.67TCr 248.05Cr 242.91Cr 9.82TCr | EV / Sales 2025 * |
3.89x | EV / Sales 2026 * | 2.26x |
| Free-Float |
99.03% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: CorMedix Inc.
More recommendations
More press releases
| 1 day | -1.90% | ||
| 1 week | -3.21% | ||
| Current month | -11.85% | ||
| 1 month | -20.03% | ||
| 3 months | +41.59% | ||
| 6 months | -10.76% | ||
| Current year | +34.07% |
| 1 week | 10.84 |  | 11.65 |
| 1 month | 10.84 | | 17.43 |
| Current year | 5.6 | | 17.43 |
| 1 year | 3.61 | | 17.43 |
| 3 years | 2.57 | | 17.43 |
| 5 years | 2.57 | | 18.8 |
| 10 years | 0.86 | | 22.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 49 | 10/05/2022 |
Mathew David
CEO | Chief Executive Officer | 48 | 04/10/2021 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Janet Dillione
BRD | Director/Board Member | 66 | 06/08/2015 |
Myron Kaplan
CHM | Chairman | 80 | 03/08/2017 |
Steven Lefkowitz
BRD | Director/Board Member | 69 | 16/08/2011 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0% | 293,477 M€ | +1.92% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.90% | -3.21% | +133.55% | +136.09% | 81Cr | ||
| -0.85% | -1.95% | -27.50% | -33.11% | 5.6TCr | ||
| -0.51% | +1.73% | -20.28% | -21.52% | 889.64Cr | ||
| -2.80% | +18.17% | +35.66% | +152.22% | 710.47Cr | ||
| -2.34% | -1.22% | +4.46% | +12.76% | 695.58Cr | ||
| -0.10% | +4.78% | +19.35% | +32.56% | 580.84Cr | ||
| +3.01% | +9.08% | +98.24% | +17.48% | 368.96Cr | ||
| +2.71% | +6.36% | +106.73% | +44.61% | 204.2Cr | ||
| -1.89% | -0.82% | -11.07% | +16.15% | 204.18Cr | ||
| -3.72% | -2.36% | +6.91% | +7.98% | 202.51Cr | ||
| Average | -0.84% | +3.22% | +34.60% | +36.52% | 954.17Cr | |
| Weighted average by Cap. | -0.89% | +1.12% | -6.76% | -3.91% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 17Cr 15Cr 14Cr 13Cr 23Cr 1.46TCr 26Cr 164.25Cr 62Cr 686.72Cr 64Cr 62Cr 2.52TCr | 25Cr 21Cr 20Cr 18Cr 34Cr 2.11TCr 38Cr 237.04Cr 89Cr 991.09Cr 92Cr 90Cr 3.64TCr |
| Net income | 7.61Cr 6.53Cr 6.08Cr 5.66Cr 10Cr 655.36Cr 12Cr 73Cr 28Cr 307.27Cr 29Cr 28Cr 1.13TCr | 13Cr 12Cr 11Cr 10Cr 18Cr 1.16TCr 21Cr 129.91Cr 49Cr 543.15Cr 50Cr 49Cr 2TCr |
| Net Debt | -15Cr -13Cr -12Cr -11Cr -20Cr -1.27TCr -23Cr -141.98Cr -54Cr -593.62Cr -55Cr -54Cr -2.18TCr | -25Cr -22Cr -20Cr -19Cr -35Cr -2.18TCr -39Cr -244.85Cr -92Cr -1.02TCr -95Cr -93Cr -3.76TCr |
More financial data
* Estimated data
Employees
65
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/25/18 | 10.86 $ | -1.90% | 14,14,182 |
| 17/25/17 | 11.07 $ | -0.54% | 12,61,214 |
| 16/25/16 | 11.13 $ | -2.11% | 16,22,337 |
| 15/25/15 | 11.37 $ | +0.09% | 12,52,511 |
| 14/25/14 | 11.36 $ | +1.25% | 13,37,308 |
Delayed Quote Nasdaq, July 19, 2025 at 01:30 am IST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.86USD
Average target price
19.14USD
Spread / Average Target
+76.27%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRMD Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition